Evidence map›Paper›PMID 32454753›Full record

ReviewTurkish journal of pharmaceutical sciences2019

Nanocarriers Used Most in Drug Delivery and Drug Release: Nanohydrogel, Chitosan, Graphene, and Solid Lipid.

Sibel Ayşıl Özkan, Aylin Dedeoğlu, Nurgül Karadaş Bakirhan, Yalçın Özkan

Abstract readReview
In one paragraph

Review in Turkish journal of pharmaceutical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sibel Ayşıl ÖzkanAnkara University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, Turkey.ORCID https://orcid.org/0000-0001-7494-3077
Aylin DedeoğluAnkara University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, Turkey.
Nurgül Karadaş BakirhanUniversity of Health Sciences, Gülhane Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, Turkey.
Yalçın ÖzkanUniversity of Health Sciences, Gülhane Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past few years, nanocarriers have become an ideal solution for safe and efficient drug delivery and release. This is mainly due to the extraordinary characteristics that nanomaterials exhibit when compared with their larger scaled forms. A variety of these carriers are more popular due to their high biocompatibility, ensuring greater efficacy especially in cancer treatments. Nanocrystal, liposomal, and micelle designs of these materials as nanocarriers for drug delivery and release have been extensively researched throughout the past 50 years. Successful applications have not only ensured a greater focus on therapeutic development but also created a new solution available in the pharmaceutical market. Herein, a brief review of research studies focused on nanocarrier materials and designs to achieve superior benefits of drugs for disease treatments is presented. Nanohydrogels, chitosan, graphene oxide, and solid lipid nanoparticle nanocarrier designs and applications are selectively given due to the great attention they have gained from being highly biocompatible and easy-to-manipulate nanocarrier options from organic and inorganic nanocarrier materials. Each summary exhibits the progress that has been achieved to date. With greater understanding of the current state in the development process of these nanomaterials, there is a rising chance to provide better treatment to patients, which is a desperate need in pharmaceutical technologies.

Indexed as

controlled drug releasedrug deliveryNanocarriernanomaterialstargeting

Identifiers

PMID32454753
PMCPMC7227887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.